<DOC>
	<DOCNO>NCT01303510</DOCNO>
	<brief_summary>A study ass whether Northern Hemisphere 2008/2009 season influenza vaccine Inflexal V fulfill EMEA requirement re-registration influenza vaccine</brief_summary>
	<brief_title>A Re-licensing Study Assess Efficacy Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains Northern Hemisphere</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Inclusion criterion : Healthy female male adult Aged ≥18 ≤60 year &gt; 60 year Day 1 Written inform consent Exclusion criterion : Acute exacerbation bronchopulmonary infection ( cough , sputum , lung finding ) acute disease Acute febrile illness ( ≥38.0 °C ) Prior vaccination influenza vaccine past 330 day Known hypersensitivity vaccine component Previous history serious adverse reaction influenza vaccine History egg protein allergy severe atopy Known blood coagulation disorder Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose study vaccine ; oral corticosteroid dosage ≥0.5 mg/kg/d prednisolone equivalent exclude ; inhale topical steroid allow Known immunodeficiency ( incl . leukemia , cancer , HIV seropositivity ) Investigational medicinal product receive past 3 month ( 90 day ) Treatment immunoglobulin blood transfusion ( ) receive past 3 month ( 90 day ) Pregnancy lactation Participation another clinical trial Employee investigational site , relative spouse investigator Suspected noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Virus</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Immunisation</keyword>
</DOC>